Pentixapharm Holding AG: management transactions · Germany · BaFin

About Pentixapharm Holding AG

Pentixapharm Holding AG is a German clinical-stage biotechnology company listed on Xetra/Frankfurt (DAX/MDAX/SDAX) under ticker PTP.DE and ISIN DE000A40AEG0. Headquartered in Berlin, Germany, the company was founded in 2019 and emerged from a spin-off of the Eckert & Ziegler group before listing on the Frankfurt Stock Exchange’s Prime Standard on 3 October 2024. For international investors, Pentixapharm sits in a high-science, high-risk segment of healthcare: radiopharmaceuticals. The company’s business model is built around innovative radiopharmaceuticals for diagnosis and therapy, following a theranostics approach that links imaging with targeted treatment. Its pipeline is centered on CXCR4-targeted assets, a biologically relevant receptor implicated in several high-unmet-need diseases. The lead diagnostic candidate is PentixaFor, a gallium-68-labeled radiodiagnostic designed to support non-invasive subtyping of primary aldosteronism in patients with treatment-resistant hypertension. On the therapeutic side, PentixaTher is a yttrium-90-based radiopharmaceutical being developed for oncology applications. Pentixapharm is also advancing an antibody-based radiolabeled platform at an earlier, preclinical stage. From a competitive standpoint, Pentixapharm operates in a specialized but strategically attractive niche. Radiopharmaceuticals combine strong scientific differentiation, high barriers to entry, and the potential for meaningful clinical and commercial value if development succeeds. The company’s positioning rests on first-in-class CXCR4-targeted programs, a growing body of clinical publications, and an increasingly visible regulatory path, especially in the United States. Its geographic footprint is primarily German, with offices in Berlin and Würzburg, while its development and regulatory ambition is clearly international. Recent company-specific news has been important. In May 2026, Pentixapharm submitted an IND application to the U.S. FDA to initiate the Phase 3 PANDA study for its lead CXCR4-targeted diagnostic program. The company also reported favorable FDA feedback on that program, which supports its registrational strategy. In 2026, Pentixapharm also received “Study May Proceed” letters for dual theranostic INDs in its CXCR4-based hematology-oncology program. In 2025, it signed a manufacturing agreement with Eckert & Ziegler for Y90-PentixaTher and subsequently announced a strategic shift to reduce early-stage R&D and focus resources on its most advanced clinical assets. Overall, Pentixapharm offers exposure to a German listed healthcare name on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany, with substantial pipeline optionality but clear clinical and regulatory execution risk.